Resistance to Targeted-TKI Treatment in Patients With CML

preview_player
Показать описание
Difference between primary and secondary resistance attributing 50% of secondary resistance to mutations and use of ponatinib in T315I mutation.

Рекомендации по теме
Комментарии
Автор

And for the mutation G250E, which TQI is better??

ofeliarouillard
welcome to shbcf.ru